Holbæk, Denmark, 19 August 2016 – Pharmacosmos announces initiation of a novel study programme to obtain FDA approval of Monofer® while continuing its search for a partner to commercialise Monofer® in the US. The study programme consists of two large-scale US trials in patients
More
“We are the best/ experts in our field/ world leaders” are just
Quotient Clinical, the Translational Pharmaceutics company, has announced the completion of its
Holbæk, Denmark, 19 August 2016 – Pharmacosmos announces initiation of a novel study programme to obtain FDA approval of Monofer®
MoreQuotient Clinical, the Translational Pharmaceutics company, has announced the completion of its first clinical program involving Japanese healthy volunteers. The
More
Traditionally, clinical study has either excluded women or not taken account of the numbers or effects of medicines of women
More[wp_ad_camp_4]Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company
More“We are the best/ experts in our field/ world leaders” are just some of the throwaway slogans employed by CROs
More
